<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03290053</url>
  </required_header>
  <id_info>
    <org_study_id>CE-5S</org_study_id>
    <nct_id>NCT03290053</nct_id>
  </id_info>
  <brief_title>Contrast Enhanced Sonothrombolysis and Sonolysis in Stroke - a Swedish Study (CE-5S)</brief_title>
  <acronym>CE-5S</acronym>
  <official_title>Contrast Enhanced Sonothrombolysis and Sonolysis in Stroke - a Swedish Study (CE-5S)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Umeå University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Umeå University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with acute ischemic stroke in anterior circulation within 4,5 hours of symptom&#xD;
      onset, has a bone window and Trombolysis In Brain Ischemia (TIBI) &lt;=4 in a relevant artery&#xD;
      eligible. Both patients receiving thrombolysis and those who do not due to contraindications&#xD;
      such as anticoagulation or recent surgery are enrolled, but into different study arms (CE-5S&#xD;
      A for thrombolysis and B for non-thrombolysis); the decision to treat with thrombolysis or&#xD;
      not is done according to clinical routine.&#xD;
&#xD;
      All included patients are randomized to receive transcranial ultrasound and SonoVue-infusion&#xD;
      or sham-ultrasound and placebo; i.e. in CE-5S A, contrast enhanced sonothrombolysis is&#xD;
      compared to thrombolysis and in CE-5S B, contrast enhanced sonolysis is compared with&#xD;
      conservative management.&#xD;
&#xD;
      Main outcome is improvement in National Institute of Health Stroke Scale (NIHSS) at 24 hours&#xD;
      compared to baseline. Main safety outcome is symptomatic intracerebral haemorrhage.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Poor inclusion rate &amp; lack of funding&#xD;
  </why_stopped>
  <start_date type="Actual">November 28, 2017</start_date>
  <completion_date type="Actual">April 18, 2018</completion_date>
  <primary_completion_date type="Actual">April 18, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Early clinical Outcome defined as change in NIHSS at 24 hours.</measure>
    <time_frame>24 hours</time_frame>
    <description>Change in National NIHSS at 24 hours. Defined reaching of primary endpoint is post-treatment 0 Points and/or improves with &gt;=4 Points compared to pre-treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety: Symptomatic Cerebral Hemorrhage (sICH)</measure>
    <time_frame>24-36 hours</time_frame>
    <description>Assessed with routine post-treatment CT head and requires an accompanied &gt;=4 Points worsening on NIHSS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long term outcome defined as residual handicap at Three months</measure>
    <time_frame>90 days</time_frame>
    <description>90-days modified Rankin Scale (mRS) reaching 0-1.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>CE-5S A: Treatment arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gets thrombolysis, transcranial ultrasound on the flow limitation and SonoVue infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CE-5S A: Control arm</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Gets thrombolysis, sham transcranial ultrasound and placebo (NaCl) infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CE-5S B: Treatment arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gets NO thrombolysis (due to contraindications), transcranial ultrasound on the flow limitation and SonoVue infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CE-5S B: Control arm</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Gets NO thrombolysis (due to contraindications), sham transcranial ultrasound and placebo (NaCl) infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SonoVue</intervention_name>
    <description>SonoVue-infusion over 1 hour</description>
    <arm_group_label>CE-5S A: Treatment arm</arm_group_label>
    <arm_group_label>CE-5S B: Treatment arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium chloride</intervention_name>
    <description>Placebo</description>
    <arm_group_label>CE-5S A: Control arm</arm_group_label>
    <arm_group_label>CE-5S B: Control arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Transcranial Ultrasound</intervention_name>
    <description>Transcranial ultrasound aimed at the blockage</description>
    <arm_group_label>CE-5S A: Treatment arm</arm_group_label>
    <arm_group_label>CE-5S B: Treatment arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Sham Transcranial Ultrasound</intervention_name>
    <description>Placebo - machine is attached, but not active</description>
    <arm_group_label>CE-5S A: Control arm</arm_group_label>
    <arm_group_label>CE-5S B: Control arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female patients ≥18 years with acute ischaemic stroke in the anterior&#xD;
             circulation, who has given written consent for his/her participation to the study.&#xD;
&#xD;
          -  Remaining neurological deficit that is ≥1 NIHSS points, sufficient to warrant&#xD;
             treatment with tPA (not taking possible contraindications into account) and is severe&#xD;
             enough that possible improvement is clearly analysable&#xD;
&#xD;
          -  Treatment &lt;4½ hours of symptom onset or of waking up in the morning with symptoms&#xD;
&#xD;
          -  Sufficient bone window for acceptable or better acquisition of flow information with&#xD;
             ultrasound with TIBI ≤ 4 in the symptomatic artery&#xD;
&#xD;
          -  In cases with women of Childbearing Capacity (WOCBC): Only if willing to comply with&#xD;
             effective contraception methods during the course of the trial. Acceptable methods are&#xD;
             such as oral contraceptives, contraceptive patches, contraceptive implant, vaginal&#xD;
             contraceptive, double-barrier methods (for example, condom and spermicide),&#xD;
             intrauterine device (IUD), hormonal IUD&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with premorbid modified Rankin Scale (mRS) score ≥3;&#xD;
&#xD;
          -  Patients for whom a complete NIHSS cannot be obtained;&#xD;
&#xD;
          -  Hemiplegic migraine with no arterial occlusion on baseline Computed Tomography of&#xD;
             brain (CT);&#xD;
&#xD;
          -  Seizure at stroke onset and no visible occlusion on baseline CT;&#xD;
&#xD;
          -  Intracranial haemorrhage on baseline CT;&#xD;
&#xD;
          -  Clinical presentation suggesting subarachnoid haemorrhage even if baseline CT is&#xD;
             normal;&#xD;
&#xD;
          -  Large areas of hypodense ischaemic changes on baseline CT;&#xD;
&#xD;
          -  Pregnancy or breast-feeding, pericarditis; sepsis; any other serious medical illness&#xD;
             likely to interact with treatment; confounding pre-existent neurological or&#xD;
             psychiatric disease; unlikely to complete follow-up; any investigational drug &lt;14&#xD;
             days;&#xD;
&#xD;
          -  Inability to provide informed consent sufficiently clearly that the study physician&#xD;
             can be convinced that informed consent has been given by the patient - such as severe&#xD;
             aphasia or coma.&#xD;
&#xD;
        Specific sonothrombolysis exclusion criteria&#xD;
&#xD;
          -  known hypersensitivity/allergy to SonoVue;&#xD;
&#xD;
          -  recent or unstable coronary ischemia or resting angina &lt;7 days;&#xD;
&#xD;
          -  acute cardiac insufficiency, cardiac insufficiency class III/IV; serious cardiac&#xD;
             arrhythmias;&#xD;
&#xD;
          -  any right-left-shunt; severe pulmonary hypertension; uncontrolled hypertension;&#xD;
&#xD;
          -  moderate to severe Chronic Obstructive Pulmonary Disease (COPD; baseline O2 saturation&#xD;
             &lt;80%);&#xD;
&#xD;
          -  acute respiratory distress syndrome (ARDS);&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elias Johansson, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Umeå University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Umeå</city>
        <state>Västerbotten</state>
        <zip>90821</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <study_first_submitted>September 14, 2017</study_first_submitted>
  <study_first_submitted_qc>September 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 21, 2017</study_first_posted>
  <last_update_submitted>May 4, 2018</last_update_submitted>
  <last_update_submitted_qc>May 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

